

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Guangzhou Innogen Pharmaceutical Group Co., Ltd.

廣州銀諾醫藥集團股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2591)

**VOLUNTARY ANNOUNCEMENT
VOLUNTARY LOCK-UP UNDERTAKING BY
THE FOUNDER OF THE GROUP AND CERTAIN SENIOR MANAGEMENT**

This announcement is made by Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the “**Company**”) on a voluntary basis to inform the shareholders of the Company and potential investors of its recent updates.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company has been informed by (i) Dr. WANG QINGHUA (“**Dr. Wang**”), founder of the Group, chairman of the Board, executive Director, general manager of the Company, and a substantial shareholder of the Company; (ii) Ms. Jiang Fan (“**Ms. Jiang**”), executive Director, shareholder of Hong Kong Invengen Pharmaceutical Technology Co., Limited (香港醫韻醫藥技術有限公司) and limited partner of Guangzhou Nuopa Enterprise Management Partnership (Limited Partnership) (廣州諾帕企業管理合夥企業(有限合夥)) (“**Guangzhou Nuopa**”), an employee incentive platform of the Company; (iii) Ms. Xu Wenjie (“**Ms. Xu**”), executive Director and limited partner of Guangzhou Nuopa; and (iv) Mr. Huang Bing (“**Mr. Huang**”), executive Director and limited partner of Guangzhou Nuopa, each of Dr. Wang, Ms. Jiang, Ms. Xu and Mr. Huang has voluntarily undertaken not to dispose of any shares or interests in the Company directly or indirectly owned by him/her for a period of six months from 15 August 2026 (i.e. the date of expiry of the lock-up period of the controlling shareholder of the Company pursuant to the global offering of the Company on the Main Board of The Stock Exchange of Hong Kong Limited) as a result of their strong confidence in the Company’s future prospect and long-term development.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the People’s Republic of China, 7 September 2026

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.